Western University Researchers Uncover Potential Link Between Common Antibiotics and Panic Attacks
Researchers at Western University in London, Ontario, have published a compelling study highlighting a possible connection between fluoroquinolone antibiotics and an elevated risk of panic attacks. This work, led by Keeirah Hiertika Raguram from the Department of Physiology and Pharmacology, analyzes data from clinical trials, case reports, and the U.S. FDA's Adverse Event Reporting System (FAERS). The findings suggest fluoroquinolones may carry a significantly higher reporting rate of panic attacks compared to other antibiotics, prompting calls for further investigation into these widely prescribed medications.
Fluoroquinolones, such as ciprofloxacin, levofloxacin, and moxifloxacin, are broad-spectrum antibiotics commonly used to treat urinary tract infections, respiratory infections, and skin infections. Their effectiveness has made them a go-to option in clinical settings, but concerns over side effects have grown over the years. This Canadian-led research adds to the conversation by focusing on central nervous system (CNS) effects, specifically panic attacks, which involve sudden episodes of intense fear or discomfort accompanied by physical symptoms like rapid heartbeat, sweating, and shortness of breath.
The study represents a milestone for student-involved research at Western University, where undergraduate and graduate students collaborate with faculty on high-impact pharmacoepidemiology projects. Such initiatives underscore the university's commitment to training the next generation of medical researchers in Canada.
Understanding Fluoroquinolone Antibiotics: Mechanism and Common Uses
Fluoroquinolones work by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair in bacteria. This mechanism disrupts bacterial growth, making these drugs potent against a range of Gram-positive and Gram-negative pathogens. In Canada, they are prescribed for conditions like complicated urinary tract infections (UTIs), chronic bacterial prostatitis, and certain pneumonias when first-line options fail.
Despite their utility, regulatory bodies like Health Canada and the FDA have issued warnings about serious adverse events, including tendon rupture, aortic aneurysm, and peripheral neuropathy. Psychiatric effects, such as anxiety, depression, and hallucinations, have also been noted, leading to black box warnings. The Western University study zeroes in on panic attacks as a under-explored phenotype within this spectrum of CNS risks.
At institutions like Western University's Schulich School of Medicine & Dentistry, pharmacology courses emphasize these risks, preparing students for evidence-based prescribing. For aspiring healthcare professionals, resources like crafting a strong academic CV can highlight such research experience when applying to higher ed jobs in pharmacology.
The Research Methods: A Rigorous Systematic Review and Database Analysis
The study employed a dual approach: a systematic review of literature from MEDLINE and Embase databases, identifying 12 relevant publications from 2004 to 2024—four randomized clinical trials and eight papers detailing 11 case reports. Panic attack prevalence in the trials varied from 0.46% to 1.76%, though wide confidence intervals indicated uncertainty due to small sample sizes.
Complementing this, researchers conducted disproportionality analyses on FAERS data (2004Q1–2024Q4), comparing fluoroquinolones to azithromycin and trimethoprim/sulfamethoxazole. Metrics included reporting odds ratios (ROR), proportional reporting ratios, and Bayesian methods to detect safety signals for the MedDRA term 'panic attack'. This pharmacovigilance technique helps identify disproportionate adverse event reporting, flagging potential risks for further study.
Such methodological sophistication is a hallmark of Canadian medical research, often supported by universities like Western, where students gain hands-on experience in big data analysis—skills transferable to careers in drug safety and regulatory affairs.
Key Findings: Sixfold Increase in Panic Attack Reports
The FAERS analysis revealed striking signals: fluoroquinolones showed a sixfold increase in panic attack reports compared to azithromycin and a 12-fold increase versus trimethoprim/sulfamethoxazole. Ciprofloxacin demonstrated the strongest association, with roughly double the risk of other fluoroquinolones like levofloxacin and moxifloxacin. These results held across multiple statistical methods, including Bayesian analyses.
While causality cannot be inferred from spontaneous reports—which are unverified and subject to reporting bias—the consistency with prior case reports strengthens the hypothesis. The researchers emphasize this as hypothesis-generating evidence, urging pharmacoepidemiological studies using longitudinal data to confirm risks in real-world populations.
Spotlight on Lead Researcher Keeirah Hiertika Raguram and the Western University Team
Keeirah Hiertika Raguram, a standout in Western University's Bachelor of Medical Sciences (BMSc) program, led this project. A recipient of the Mogenson Trust Physiology Undergraduate Award, Raguram exemplifies how Canadian universities empower students to contribute to peer-reviewed publications early in their careers. Collaborators include Manroop Sidhu, Mohammad Ali Omrani, Bala Swetha Baskaran, Niaz Wahid, Tyler G. K. Marshall, and Davinder S. Parmar, all from Western's Department of Physiology and Pharmacology.
This multidisciplinary team highlights Western University's collaborative environment, where faculty mentor students on cutting-edge topics like drug safety pharmacovigilance. For those interested in similar paths, Western offers robust opportunities in Canadian higher ed, and platforms like Rate My Professor provide insights into faculty guiding such research.
Known Psychiatric Risks of Fluoroquinolones: Building on Prior Evidence
Fluoroquinolones' CNS effects stem from GABA receptor antagonism and GABA-glutamate imbalance, potentially exacerbated by gut microbiome disruption via the gut-brain axis. Previous studies, including FDA analyses, link them to anxiety, insomnia, delirium, and depression. A 2024 Frontiers study using FAERS confirmed psychiatric ADRs, with anxiety disorders topping reports.
In Canada, Health Canada's 2017 review assessed persistent disabling effects, reinforcing restrictions. The Western study extends this by isolating panic attacks, a discrete entity differing from generalized anxiety or panic disorder (a chronic condition with recurrent attacks).
Canadian universities like Western are at the forefront, training pharmacologists to navigate these complexities. Explore research assistant jobs to join such teams.
Implications for Canadian Healthcare and Prescribing Practices
With fluoroquinolones reserved for serious infections per guidelines, this research reinforces antibiotic stewardship. In Canada, where antimicrobial resistance rises, balancing efficacy and safety is crucial. Clinicians may prioritize alternatives like beta-lactams for susceptible infections, especially in patients with psychiatric history.
Health Canada's MedEffect monitors such signals, and this study could inform label updates. For medical students at universities nationwide, it underscores pharmacovigilance's role in patient safety.
Read the full Western University studyWestern University's Legacy in Pharmacology and Drug Safety Research
Western University's Department of Physiology and Pharmacology boasts a storied history in neuroscience and pharmacology, with faculty publishing in top journals. Schulich School integrates research into curricula, fostering student-led projects like this one. Amid Canada's push for research excellence, Western ranks highly, attracting talent via scholarships and labs.
Graduates often secure roles in pharma, regulatory agencies, or academia. Check university jobs or career advice for pathways.
Case Reports and Real-World Examples from the Literature
The systematic review cataloged 11 cases where panic attacks emerged shortly after fluoroquinolone initiation, resolving upon discontinuation. One report described severe episodes mimicking myocardial infarction, highlighting diagnostic challenges. These anecdotes, while limited, align with FAERS signals.
In Canada, similar reports to Health Canada underscore vigilance. Researchers note vulnerability in elderly or those with psychiatric predispositions.
PubMed entry for the studyRegulatory Perspectives: FDA, Health Canada, and Global Warnings
The FDA's 2018 update added mental health risks, requiring label changes. Health Canada's reviews echo concerns over disabling effects. EMA restricts fluoroquinolones to severe cases. This study bolsters evidence for tighter guidelines.
Canadian higher ed plays a key role, with universities training regulators. Link to Canadian academic opportunities.
Future Directions: Calls for Large-Scale Studies and Stewardship
Raguram et al. advocate population-based cohort studies to quantify absolute risks and identify susceptible groups. Gut-brain axis research could elucidate mechanisms. Enhanced stewardship in Canadian hospitals could mitigate misuse.
Western University plans follow-ups, exemplifying sustained impact.
Photo by Melany @ tuinfosalud.com on Unsplash
Why This Matters for Students, Researchers, and Healthcare Professionals
This study showcases how university research translates to public health. For students eyeing medicine or pharmacology, it highlights rewarding careers. AcademicJobs.com connects talent to faculty positions, postdoc roles, and more. Rate your professors and explore career advice. Stay informed on cutting-edge Canadian research driving safer healthcare.